alagebrium has been researched along with thiamine in 4 studies
| Studies (alagebrium) | Trials (alagebrium) | Recent Studies (post-2010) (alagebrium) | Studies (thiamine) | Trials (thiamine) | Recent Studies (post-2010) (thiamine) |
|---|---|---|---|---|---|
| 83 | 10 | 31 | 10,675 | 302 | 1,838 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imaizumi, T; Yamagishi, S | 1 |
| Nakamura, J | 1 |
| Forbes, J; Griffith, R; Horne, S; Krautwald, M; Leech, D; Münch, G; Rahmadi, A; Steele, ML | 1 |
| Engelen, L; Schalkwijk, CG; Stehouwer, CD | 1 |
3 review(s) available for alagebrium and thiamine
| Article | Year |
|---|---|
[Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors].
Topics: Animals; Clinical Trials as Topic; Depression, Chemical; Diabetic Angiopathies; Glycation End Products, Advanced; Guanidines; Humans; Oxidative Stress; Pyridoxamine; Thiadiazoles; Thiamine; Thiazoles; Thiazolidines | 2005 |
[Development of therapeutic agents for diabetic neuropathies].
Topics: Aldehyde Reductase; Antioxidants; C-Peptide; Diabetic Neuropathies; Drug Design; Enzyme Inhibitors; Genetic Therapy; Glycation End Products, Advanced; Hedgehog Proteins; Humans; Indoles; Maleimides; Nerve Growth Factor; Oxidative Stress; Polymers; Protein Kinase C; Rhodanine; Thiadiazoles; Thiamine; Thiazoles; Thiazolidines; Trans-Activators; Vascular Endothelial Growth Factor A | 2005 |
Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Enzyme Inhibitors; Evidence-Based Medicine; Female; Glycation End Products, Advanced; Guanidines; Humans; Hyperglycemia; Male; Pyridoxamine; Thiamine; Thiazoles; Treatment Outcome | 2013 |
1 other study(ies) available for alagebrium and thiamine
| Article | Year |
|---|---|
The advanced glycation end product-lowering agent ALT-711 is a low-affinity inhibitor of thiamine diphosphokinase.
Topics: Animals; Binding Sites; Cattle; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Enzyme Assays; Glycation End Products, Advanced; Inhibitory Concentration 50; Kidney; Kinetics; Models, Molecular; Nucleoside-Diphosphate Kinase; Protein Kinase Inhibitors; Thiamine; Thiamine Pyrophosphate; Thiazoles | 2011 |